Drug Discovery Research

Our drug discovery research focuses on identifying well-validated clinical and commercial-stage compounds and establishing a scientific rationale for development in modern orphan drug indications. Through our relationship with Valent Technologies, LLC ("Valent"), a company owned by Dr. Dennis Brown, our Chief Scientific Officer, we are able to utilize Valent's proprietary ChemEstateā„¢ bioinformatics tools which are used to screen and identify potential candidates.

Promising candidates are further researched through our network of consultants and contract research organizations.

This approach allows us to rapidly identify and advance potential drug candidates without significant investment in "wet lab" infrastructure.

Based on this strategy, we acquired the initial VAL-083 intellectual property and prototype drug product from Valent and have identified additional drug candidates that we may have the opportunity to licenseor acquire in the future.

VAL-083 Development Strategy

Clinical validation process graphic